NCT04208126 Early Versus Late Initiation of ECMO (Extracorporal Membrane Oxygenation) Trial (ELIEO-Trial)
| NCT ID | NCT04208126 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Acute Respiratory Distress Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 508 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 508 participants in total. It began in 2025-03-01 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial is a prospective randomized multicenter trial that assigns patients to either a treatment for Acute Respiratory Distress Syndrome (ARDS) with an Extracorporal Membrane Oxygenation (ECMO) immediately after admission to the intensive care unit or conservative treatment. The later can undergo ECMO following failure of conservative therapy as a rescue therapy. Patients will be included within 24 hours of the onset of symptoms of ARDS and will be randomized according to standard procedure. Follow-up will be performed until day 90 after study inclusion.
Eligibility Criteria
Inclusion Criteria: * ARDS as defined according to the Berlin Definition1 * The term "acute onset" is defined as follow: the duration of the hypoxemia criterion and the chest radiograph criterion must be ≤ 7 days at the time of randomization. * Patients must be enrolled within 96 hours of onset of ARDS and no later than 7 days from the initiation of mechanical ventilation. Exclusion Criteria: * Age less than 18 years * More than 7 days since initiation of mechanical ventilation * more than 96 hours since meeting inclusion criteria * patient, surrogate or physician not committed to full intensive care support * pregnancy
Contact & Investigator
Peter Rosenberger, Prof.
PRINCIPAL INVESTIGATOR
University Hospital Tübingen
Frequently Asked Questions
Who can join the NCT04208126 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Respiratory Distress Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04208126 currently recruiting?
Yes, NCT04208126 is actively recruiting participants. Contact the research team at peter.rosenberger@med.uni-tuebingen.de for enrollment information.
Where is the NCT04208126 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT04208126 clinical trial?
NCT04208126 is sponsored by University Hospital Tuebingen. The principal investigator is Peter Rosenberger, Prof. at University Hospital Tübingen. The trial plans to enroll 508 participants.